Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XTX101 |
Trade Name | |
Synonyms | XTX 101|XTX-101 |
Drug Descriptions |
XTX101 is an anti-CTLA4 antibody engineered for tumor microenvironment-specific activity, which may lead to proliferation of CD8+ T lymphocytes, activation of T lymphocyte function, and tumor regression (Journal for ImmunoTherapy of Cancer 2020;8) |
DrugClasses | CTLA4 Antibody 32 |
CAS Registry Number | NA |
NCIT ID | C180687 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + XTX101 | Pembrolizumab XTX101 | 0 | 1 |
XTX101 | XTX101 | 0 | 1 |